Tigermed Finalizes Divestiture of Shanghai Guanhe Medical's Entire Equity

Stock News03-03 19:08

Tigermed (03347) has announced the completion of the sale of all issued shares of Shanghai Guanhe Medical Technology Co., Ltd. All conditions outlined in the share transfer agreement have been fulfilled, and the transaction was finalized on March 3, 2026, in accordance with the terms of the agreement. Following the sale, the target company and its subsidiaries, collectively referred to as the target group, will continue to operate as subsidiaries of Tigermed. The financial results of the target group will be consolidated into the financial statements of the Fangda Group. As the transaction is an internal transfer within the group, it is not expected to have any material impact on the group's consolidated financial position.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment